�X��������t���Ĥ��q���ƪ��������ǡ]Hans Peter
Hasler�^�h���ܡA�b���ꤴ���\�h�e�f�E�ݷs���Ī��v���A�ڭ̪����Ȥ���N�O���f�w���ѧ�n�������A�ȡC��AOP�O�ڬw�u�f�Ī�����ɼt�ӡA���Ӥ]�N�����ī~����o�i�Φ�P�M�~���s���ߪ��o�a���q�C�ڭ̴��ݸ��Q�w�ҳդh�M�L���ζ��@�_�X�@�A�H�K�b�s�Ĭ�o�v�����J�w�ɵ{�W����e�i�C
The unparalleled quick uptake and progress of PROUD-PV, completing enrollment of over 260 patients in around 15 months, proves the eagerness of both patients and physicians for this new treatment paradigm��, said Dr. Rudolf Widmann, CEO of AOP Orphan. Results from a phase I/II trial sponsored and conducted by AOP Orphan presented at ASH (American Society of Hematology) in 2012, 2013 and 2014 appear very encouraging: the overall clinical response rate including reduction of
red and white blood cells and platelets was around 90% and after 6 to 12 months of treatment, 45-50% of patients even showed complete response. Importantly, after one year all patients were completely independent from phlebotomies. In addition, all patients remaining in this trial could be switched to an even more convenient monthly treatment schedule.
���ѦA�פW����x�����ClinicalTrials.gov�d�ݸ�ơA�o�Ӻ����O�̾�1997�~����the Food and Drug Administration Modernization Act (FDAMA)�k�סA�b2000�~�Ѱ�a���ĹϮ��](NLM)�έ��ĸp(FDA)�@�P�إߪ��A�Ҧ��s���{�ɸ���L�{�������b�o�өx������W���S�A�_�h�N����k���g�B�C
��过�A�@��纳税�H�]����L计�E�C�_���̤j��药�к֧Q�z���q�X�X�ֱ�药�褽�q�]Express Scripts�^�K�O�䤤���@�A该���q�w�O��B维�N�@��独�a协议进��F谈�P�A�}�D发�F��关���x药�~���@场ɲ��战�C该���qCMO Steve Miller���ܡA计�E���ΦP样��战���A��击��L�e�f领��]�p���g�^��断�W长��药�~ɲ��C
�w���ĥثe�w���Q�@�����~�V����ԢҢϴ���u²�Ʒs�ĤW���ӽ�(Abbreviated
New Drug Application, ANDA)�v�A�ثe�֭p�w���������~���o����ԢҢϮֵo���ǦW���ҡA�w���w���Ĭ���l���q�Ĥ@�u���i���Q���o���꤭�Q�{�P��\�i�A�G�w���o����ԢҢϮ֭㪺�ǦW�ġA�i��Ĥ@�u�b���곰��}��C
